IONS · XBRL financial data

Ionis Pharmaceuticals financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (IONS's year ends in late December)

In millions of dollars	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q3 FY25Sep 30, 2025	Q2 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	—	—	325	—	—	—	227	—	—	203	—	—
Revenue from contracts with customers	188	144	325*	119	225	134	227*	132	157	203*	246	268
Cost of goods and services sold	3	2	3*	2	4	1	4*	1	2	8*	3	3
Research and development	—	—	year only	—	—	—	year only	—	—	year only	—	—
Selling, general and administrative	46	70	71*	53	65	62	88*	76	97	130*	150	150
Operating income (loss)	(90)	(143)	(6)	(150)	(66)	(149)	(111)	(147)	(160)	(214)	(117)	(102)
Interest expense	2	4	5*	4	4	4	4*	4	4	5*	5	5
Other income (expense)	11	2	0*	0	1	0	0*	0	0	(16)*	(0)	1
Income tax expense (benefit)	8	7	6*	0	0	(4)	(3)*	0	0	1*	0	1
Net income (loss)	(85)	(147)	(9)	(143)	(66)	(140)	(104)	(147)	(129)	(229)	(93)	(115)
Earnings per share, basic USD per share	(0.60)	(1.03)	(0.06)	(0.98)	(0.45)	(0.95)	(0.66)	(0.93)	(0.80)	(1.41)	(0.56)	(0.69)
Earnings per share, diluted USD per share	(0.60)	(1.03)	(0.06)	(0.98)	(0.45)	(0.95)	(0.66)	(0.93)	(0.80)	(1.41)	(0.56)	(0.69)
Weighted average shares, basic millions of shares	143	143	144*	146	146	149	158*	159	160	—	165	165
Weighted average shares, diluted millions of shares	143	143	144*	146	146	149	158*	159	160	—	165	165

Balance sheet

CSV

Fiscal quarters (IONS's year ends in late December)

In millions of dollars	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q3 FY25Sep 30, 2025	Q2 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	425	352	399	349	294	335	242	264	338	372	173	350
Short-term investments	1,961	1,884	1,932	1,857	1,785	2,149	2,056	1,881	1,902	2,305	1,746	1,705
Marketable securities	1,541	1,338	1,311	1,303	1,341	1,495	1,403	1,234	1,283	1,579	1,118	1,137
Marketable securities, non-current	457	547	653	568	461	690	653	681	701	774	631	647
Inventory	26	26	28	30	29	28	13	12	10	10	6	51
Total current assets	2,617	2,585	2,642	2,416	2,329	2,714	2,620	2,419	2,519	2,991	2,937	2,491
Property and equipment, net	92	71	71	73	76	83	94	103	106	123	142	155
Right-of-use asset	177	174	172	169	167	164	162	159	242	239	235	232
Total assets	2,971	2,934	2,990	2,764	2,691	3,081	3,004	2,813	3,033	3,524	3,450	2,995
Accounts payable	24	6	26	13	9	9	43	17	14	28	26	48
Accrued liabilities	105	119	148	106	114	124	108	103	99	106	127	116
Current portion of long-term debt	—	—	0	—	—	—	0	—	—	432	—	—
Total current liabilities	288	404	448	328	306	305	309	250	903	782	717	316
Long-term debt	—	—	1,241	—	—	—	1,202	—	—	1,328	—	—
Lease liability, non-current	175	173	171	169	166	168	162	159	263	262	259	262
Total liabilities	2,543	2,619	2,603	2,467	2,427	2,419	2,415	2,337	2,415	3,035	2,959	2,555
Accumulated deficit	(1,639)	(1,787)	(1,796)	(1,939)	(2,005)	(2,145)	(2,250)	(2,397)	(2,402)	(2,631)	(2,724)	(2,838)
Total stockholders' equity	428	315	387	297	264	662	588	476	618	489	491	440
Total liabilities and equity	2,971	2,934	2,990	2,764	2,691	3,081	3,004	2,813	3,033	3,524	3,450	2,995
Common shares outstanding (cover page) millions of shares	143	143	146	146	146	158	159	159	162	159	165	166

Cash flows

CSV

Fiscal quarters (IONS's year ends in late December)

In millions of dollars	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q3 FY25Sep 30, 2025	Q2 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(85)	(147)	(9)	(143)	(66)	(140)	(104)	(147)	(129)	(229)	(93)	(115)
Stock-based compensation	27*	26*	26*	31	31*	32*	36*	30	31*	43*	43	46*
Net cash from operating activities	(97)*	(109)*	33*	(150)	(120)*	(115)*	(116)*	(151)	(131)*	(138)*	(793)	566*
Purchases of property and equipment	12*	2*	(1)*	4	6*	9*	25*	13	5*	21*	22	16*
Net cash from investing activities	70*	69*	(27)*	76	62*	(341)*	68*	170	91*	(420)*	537	23*
Proceeds from issuing common stock	—	—	0*	—	—	—	0*	—	—	0*	—	—
Net cash from financing activities	144*	(32)*	41*	24	3*	496*	(44)*	2	81*	591*	57	(412)*
Net change in cash	116*	(73)*	47*	(50)	(55)*	41*	(93)*	22	41*	34*	(199)	177*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Ionis Pharmaceuticals	350	268	566*	166.2M	—	Q2 FY26 10-QJun 30, 2026
Madrigal Pharmaceuticals	515	431	121*	23.2M	—	Q3 FY26 10-QSep 30, 2026
Alkermes	631	480	93*	168.0M	—	Q3 FY26 10-QSep 30, 2026
Repligen	727	209	43*	63.9M	—	Q3 FY26 10-QSep 30, 2026
Corcept Therapeutics	99	340	143*	109.4M	—	Q3 FY26 10-QSep 30, 2026
Halozyme Therapeutics	163	481	241*	113.5M	—	Q2 FY26 10-QJun 30, 2026
Jazz Pharmaceuticals	2,036	1,243	506*	64.2M	—	Q3 FY26 10-QSep 30, 2026
Axsome Therapeutics	314	260	(9.5)*	52.6M	14.7 quarters	Q3 FY26 10-QSep 30, 2026
Lantheus Holdings	593	388	92*	65.3M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.